Canaccord Genuity Maintains Buy on Allogene Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) but lowers the price target from $35 to $14.
August 08, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Canaccord Genuity maintains a Buy rating on Allogene Therapeutics but significantly lowers the price target from $35 to $14.
The lowered price target from $35 to $14 indicates a significant reduction in expected future performance, which could negatively impact investor sentiment in the short term despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100